Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics

18 Mar 2020

Abstract excerpt

BackgroundLamotrigine (LTG) is an antiseizure drug (ASD) which was approved by the US Food and Drug Administration (FDA) in 1994 to treat focal (partial) seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in both children and adults.It was evaluated for several mood disorders and subsequently also approved for maintenance of bipolar disorder in adults...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to HIV/AIDS drug development and treatment
Share to Pharmacological Effects and Toxicity Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32187155
DOI: 10.1097/fpc.0000000000000397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamicsPMID 32187155Read ↗

PharmGKB summary: carbamazepine pathway.Semantic proximity Read ↗

Review or Updates on the clinical pharmacokinetics of levetiracetamSemantic proximity Read ↗

UGT1A4*3 polymorphism influences serum concentration and therapeutic effect of lamotrigine for epilepsy treatment: A meta-analysis.Semantic proximity Read ↗

Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy.Semantic proximity Read ↗

Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With EpilepsySemantic proximity Read ↗

A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy.Semantic proximity Read ↗

Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients.Semantic proximity Read ↗

Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.Semantic proximity Read ↗

PharmGKB summary: citalopram pharmacokinetics pathway.Semantic proximity Read ↗

PharmGKB summary: phenytoin pathway.Semantic proximity Read ↗

GWAS identifies two susceptibility loci for lamotrigine-induced skin rash in patients with epilepsy.Semantic proximity Read ↗

Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.